Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Pulmatrix stock opened at $6.13 on Tuesday. Pulmatrix has a twelve month low of $1.72 and a twelve month high of $10.40. The firm has a market cap of $22.37 million, a PE ratio of -2.32 and a beta of 1.38. The firm’s 50 day moving average price is $6.36 and its two-hundred day moving average price is $6.43.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.50) EPS for the quarter. Pulmatrix had a negative return on equity of 45.97% and a negative net margin of 96.51%.

Institutional Trading of Pulmatrix

An institutional investor recently raised its position in Pulmatrix stock. Geode Capital Management LLC boosted its position in shares of Pulmatrix, Inc. (NASDAQ:PULM) by 24.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,871 shares of the biotechnology company’s stock after acquiring an additional 7,290 shares during the period. Geode Capital Management LLC owned 1.01% of Pulmatrix worth $257,000 at the end of the most recent quarter. 11.84% of the stock is currently owned by institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.